Ignite Creation Date:
2025-12-25 @ 2:00 AM
Ignite Modification Date:
2026-03-07 @ 10:44 PM
Study NCT ID:
NCT02805660
Status:
TERMINATED
Last Update Posted:
2021-04-06
First Post:
2016-06-10
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC
Sponsor:
Mirati Therapeutics Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-06-01
Start Date Type:
ACTUAL
Primary Completion Date:
2019-12-14
Primary Completion Date Type:
ACTUAL
Completion Date:
2019-12-20
Completion Date Type:
ACTUAL
First Submit Date:
2016-06-10
First Submit QC Date:
None
Study First Post Date:
2016-06-20
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2020-12-11
Results First Submit QC Date:
None
Results First Post Date:
2021-04-06
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-03-10
Last Update Post Date:
2021-04-06
Last Update Post Date Type:
ACTUAL